SCHEMBL118043

SCHEMBL118043

Fc1ccc(OCCBr)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
DRD2 P14416 2/20 0.47
DRD4 P21917 2/20 0.47
DRD3 P35462 2/20 0.47
LTA4H P09960 1/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
MAOB P27338 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427333 0.88 DRD2 (0.50) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL8140756 0.87 NPC1 (0.47) L3MBTL1LTA4HRAB9ANPC1ALDH1A1
SCHEMBL3098656 0.86 MEN1 (0.51) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL9114592 0.85 CYP1A2 (0.63) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL15922927 0.85 MEN1 (0.54) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL6750345 0.85 MEN1 (0.54) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL7388659 0.85 MEN1 (0.54) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL27515741 0.83 MEN1 (0.46) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL10338308 0.82 MEN1 (0.60) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1
SCHEMBL27517121 0.81 MEN1 (0.49) CYP1A2CYP2D6CYP2C19TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105872-B Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2024-10-15 CN claimed
CN-117105872-A Benzodiazepine compound and preparation method and application thereof 徐州医科大学 2023-11-24 CN claimed
EP-0288360-A1 Derivatives of 1-[(1,1-diphenyl)-1-alkenyl] piperazine, process for their preparation and compositions containing them Société anonyme: LES LABORATOIRES MERAM (FR) 1988-10-26 EP claimed
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 US disclosed
US-12390463-B2 Dosage forms and regimens for amino acid compounds PLIANT THERAPEUTICS, INC. (US) 2025-08-19 US disclosed
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2025-07-10 US disclosed
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-120058445-A Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method 华东师范大学 2025-05-30 CN disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
US-4882331-A ANTIDEPRESSANTS LES LABORATOIRES MERAM (FR) 1989-11-21 US disclosed
US-4841079-A Process for the production of asymmetric hydantoins PFIZER, INC. (US) 1989-06-20 US disclosed
EP-0288360-A1 Derivatives of 1-[(1,1-diphenyl)-1-alkenyl] piperazine, process for their preparation and compositions containing them Société anonyme: LES LABORATOIRES MERAM (FR) 1988-10-26 EP disclosed
EP-0172719-B1 PROCESS FOR THE PRODUCTION AS ASYMMETRIC HYDANTOINS PFIZER INC. (US) 1988-09-21 EP disclosed
US-4716113-A Process for the production of an (S)-methyl or (S)-ethyl 4-amino-6-fluorochroman-4-carboxylate PFIZER INC. (US) 1987-12-29 US disclosed
EP-0172719-A1 Process for the production as asymmetric hydantoins PFIZER INC. (US) 1986-02-26 EP disclosed
US-4027028-A HYPOTENSIVE AGENTS SCIENCE UNION ET CIE (FR) 1977-05-31 US disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 US disclosed
US-3991202-A ANTIMICROBIALS JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390463-B2 Dosage forms and regimens for amino acid compounds ITGB6, ITGA6, ITGAV CYP1A2 3905/4885CYP2D6 1900/4885CYP2C19 2802/4885
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA6, ITGA5 CYP1A2 4533/4885CYP2D6 3537/4885CYP2C19 3771/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CYP1A2 1871/4885CYP2D6 1219/4885CYP2C19 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.